Difference between revisions of "Advanced Tissue Sciences"
m |
m (adjust REF... parameters) |
||
| Line 52: | Line 52: | ||
Advanced Tissue Sciences has sold about $1 million worth of cultured dermis to Proctor & Gamble, Helene Curtis, and other such businesses for pre-market testing. Advanced Tissue Science's foreskin-derived merchandise held a $32 million stock offering in the beginning of 1992.<ref>{{REFbook | Advanced Tissue Sciences has sold about $1 million worth of cultured dermis to Proctor & Gamble, Helene Curtis, and other such businesses for pre-market testing. Advanced Tissue Science's foreskin-derived merchandise held a $32 million stock offering in the beginning of 1992.<ref>{{REFbook | ||
| − | | last=Pitta | + | |last=Pitta |
| − | | first=Julie | + | |first=Julie |
| − | | date=10 | + | |date=1993-05-10 |
| − | | title=Biosynthetics | + | |title=Biosynthetics |
| − | | url= | + | |url= |
| − | | editor= | + | |editor= |
| − | | edition= | + | |edition= |
| − | | volume= | + | |volume= |
| − | | chapter= | + | |chapter= |
| − | | pages=170-171 | + | |pages=170-171 |
| − | | location= | + | |location= |
| − | | publisher=Forbes | + | |publisher=Forbes |
| − | | isbn= | + | |isbn= |
| − | | accessdate= | + | |accessdate= |
| − | | note=The 32-page Advanced Tissue Sciences, Inc. 1997 Annual Report refers to "fibroblasts" but does not contain the word "foreskin." | + | |note=The 32-page Advanced Tissue Sciences, Inc. 1997 Annual Report refers to "fibroblasts" but does not contain the word "foreskin." |
}}</ref> | }}</ref> | ||
Revision as of 21:00, 11 November 2019
Advanced Tissue Sciences is a corporation based in La Jolla, CA. They are the makers of Dermagraft-TC, which is an artifical skin created from harvested foreskins from infant circumcision.[1] They are also the makers of NouriCel, another product made from harvested foreskins,[2] and one of the main ingredients of SkinMedica's TNS Recovery Complex product.[3]
Earnings
Dermagraft-TC is FDA approved,[4][5] and it sells for about $3,000 per square foot and one foreskin contains enough genetic material to grow 250,000 square feet of skin.[6]
Advanced Tissue Sciences has sold about $1 million worth of cultured dermis to Proctor & Gamble, Helene Curtis, and other such businesses for pre-market testing. Advanced Tissue Science's foreskin-derived merchandise held a $32 million stock offering in the beginning of 1992.[7]
In 1996 alone, Advanced Tissue Sciences could boast of a healthy $663.9 million market capitalization performance.[8]
References
- ↑
Dermagraft-TC: Overview
, Advanced Biohealing, Inc.. Retrieved 6 March 2011.
Quote:Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue.
- ↑
The Foreskin Mafia
, Acroposthion.com. Retrieved 6 March 2011.
Quote:TNS contains... NouriCel-MD which is... a combination of Natural Growth Factors, matrix proteins, and soluble collagen. Human Growth Factors extracted from cultured cells of foreskin...
- ↑
SkinMedica Introduces TNS Recovery Complex
, SkinMedica. Retrieved 6 March 2011.
Quote:TNS Recovery Complex is the only product containing a professional concentration of NouriCel®, a new cosmetic ingredient from leading tissue-engineering company Advanced Tissue Sciences.
- ↑ (2011).
Dermagraft-TC: General Information: Advanced Tissue Sciences
, MediLexicon International Ltd. Retrieved 7 May 2011.
Quote:Dermagraft-TC is the first human, fibroblast-derived temporary skin substitute for the treatment of partial-thickness burns that has been approved for marketing by the FDA.
- ↑ (28 March 1997).
Transplant News: Advanced Tissue Sciences' temporary wound covering Dermagraft-TC approved for marketing by FDA
, HighBeam Research. Retrieved 7 May 2011.
Quote:the Food and Drug Administration has approved Dermagraft-TC
- ↑ Circumcision. Daecher M. Icon 1998;2(2):70-3.
- ↑
Pitta, Julie: Biosynthetics. Forbes. Pp. 170-171.
Note: The 32-page Advanced Tissue Sciences, Inc. 1997 Annual Report refers to "fibroblasts" but does not contain the word "foreskin." - ↑ Biotech's Big Discovery. Hall CT. San Francisco Chronicle. October 25, 1996: E1, E4.
